Free Trial
→ Claim Your Share of $5.39 BILLION in AI Equity Checks (From Angel Publishing) (Ad)tc pixel

Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 4.5% - Here's What Happened

Written by MarketBeat
Updated September 20, 2025
Ascentage Pharma Group International logo with Medical background

Key Points

  • Ascentage Pharma Group International (NASDAQ:AAPG) experienced a 4.5% decline in stock price, trading at $38.63, down from a previous close of $40.46.
  • In the second quarter, several hedge funds, including Chevy Chase Trust Holdings LLC and Hsbc Holdings PLC, made new investments in the company.
  • The company focuses on developing therapies for cancers, hepatitis B virus, and age-related diseases, and is classified as a clinical-stage biotechnology firm.
  • Five stocks we like better than Ascentage Pharma Group International.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s stock price fell 4.5% on Monday . The company traded as low as $38.63 and last traded at $38.63. 10,974 shares were traded during mid-day trading, a decline of 3% from the average session volume of 11,279 shares. The stock had previously closed at $40.46.

Ascentage Pharma Group International Stock Down 1.3%

The firm's 50 day moving average is $40.83 and its 200 day moving average is $31.26. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Chevy Chase Trust Holdings LLC acquired a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth $227,000. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth $391,000. Tema Etfs LLC acquired a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth $610,000. Finally, Monashee Investment Management LLC bought a new stake in shares of Ascentage Pharma Group International during the 1st quarter worth $3,511,000.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Featured Stories

Should You Invest $1,000 in Ascentage Pharma Group International Right Now?

Before you consider Ascentage Pharma Group International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.

While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.